➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Merck
Boehringer Ingelheim
McKesson
Colorcon
Express Scripts

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

ADHANSIA XR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Adhansia Xr, and what generic alternatives are available?

Adhansia Xr is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are ten patents protecting this drug.

This drug has twenty-four patent family members in seventeen countries.

The generic ingredient in ADHANSIA XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

Summary for ADHANSIA XR
International Patents:24
US Patents:10
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for ADHANSIA XR
DailyMed Link:ADHANSIA XR at DailyMed
Drug patent expirations by year for ADHANSIA XR
Drug Prices for ADHANSIA XR

See drug prices for ADHANSIA XR

US Patents and Regulatory Information for ADHANSIA XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-004 Feb 27, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-003 Feb 27, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-005 Feb 27, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-006 Feb 27, 2019 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.